Levosimendan Carinopharm (Levosimendan)

Levosimendan sensitises cardiac troponin C to calcium, which enhances myocardial contractility without increasing intracellular calcium. At the same time it opens ATP‑sensitive potassium channels in vascular smooth muscle, producing arterial and venous vasodilation that lowers preload and afterload.

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s clinical status, weight, and response to therapy. The prescriber will set the infusion rate, duration, and any loading dose according to local guidelines and product labeling.

Safety data for levosimendan in pregnancy and lactation are limited. Because the potential risks to the fetus or infant are unknown, the drug should be used only if the potential benefit justifies the possible risk, and it is generally avoided during pregnancy and breastfeeding.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

Compared with traditional inotropes such as dobutamine, levosimendan increases contractility by calcium sensitisation rather than raising intracellular calcium, which may reduce the risk of calcium‑overload arrhythmias. It also adds vasodilatory effects, whereas milrinone provides phosphodiesterase inhibition without calcium sensitisation. Choice depends on patient profile and clinical goals.

Levosimendan Carinopharm should be stored at 2‑8 °C in a refrigerator. Keep the vial protected from light, do not freeze, and avoid shaking. Once reconstituted, use the solution within the time frame specified in the product label and discard any remaining material after that period.

Levosimendan is given as an intravenous infusion. After reconstitution, the solution is administered through a controlled infusion pump, typically starting with a loading dose followed by a continuous maintenance infusion, with the rate adjusted according to blood pressure, heart‑rate, and hemodynamic response.

The most serious adverse events include severe hypotension, ventricular arrhythmias, and myocardial ischemia. Continuous monitoring of blood pressure, ECG, and cardiac biomarkers is essential during infusion, and prompt intervention is required if any of these complications arise.

Levosimendan is contraindicated in patients with severe hypotension (systolic blood pressure < 90 mmHg), mechanical obstruction of ventricular outflow, recent myocardial infarction with ongoing ischemia, and in those with known hypersensitivity to the drug or any of its excipients.